MCID: CNJ005
MIFTS: 15

Conjunctival Vascular Disease malady

Categories: Eye diseases, Cardiovascular diseases

Aliases & Classifications for Conjunctival Vascular Disease

Aliases & Descriptions for Conjunctival Vascular Disease:

Name: Conjunctival Vascular Disease 12
Vascular Abnormalities of Conjunctiva 12
Vascular Abnormality of Conjunctiva 69
Conjunctival Vascular Abnormality 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10989
ICD10 33 H11.41
ICD9CM 35 372.74
NCIt 47 C35116
SNOMED-CT 64 193900004 74100001
UMLS 69 C0042370

Summaries for Conjunctival Vascular Disease

MalaCards based summary : Conjunctival Vascular Disease, is also known as vascular abnormalities of conjunctiva, and has symptoms including injected eye The drugs Latanoprost and Travoprost have been mentioned in the context of this disorder. Affiliated tissues include eye.

Related Diseases for Conjunctival Vascular Disease

Symptoms & Phenotypes for Conjunctival Vascular Disease

UMLS symptoms related to Conjunctival Vascular Disease:


injected eye

Drugs & Therapeutics for Conjunctival Vascular Disease

Drugs for Conjunctival Vascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Latanoprost Approved, Investigational Phase 4,Phase 2 130209-82-4 5282380 5311221
2
Travoprost Approved Phase 4 157283-68-6 5282226
3
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 2 155206-00-1 5311027
4
Temazepam Approved Phase 4,Phase 3 846-50-4 5391
5
Timolol Approved Phase 4 26839-75-8 33624 5478
6
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
7
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
8
Fluorouracil Approved Phase 4 51-21-8 3385
9
Maleic acid Experimental Phase 4 110-16-7 444266
10 Antihypertensive Agents Phase 4,Phase 3,Phase 2
11 Ophthalmic Solutions Phase 4,Phase 2
12 Tetrahydrozoline Phase 4,Phase 2
13 Mitogens Phase 4,Phase 2,Phase 3
14 Anti-Inflammatory Agents Phase 4,Phase 3
15 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3
16 Anti-Anxiety Agents Phase 4,Phase 3
17 Central Nervous System Depressants Phase 4,Phase 3
18 GABA Agents Phase 4,Phase 3
19 GABA Modulators Phase 4,Phase 3
20 Hypnotics and Sedatives Phase 4,Phase 3
21 Neurotransmitter Agents Phase 4,Phase 3
22 Psychotropic Drugs Phase 4,Phase 3
23 Tranquilizing Agents Phase 4,Phase 3
24 Adrenergic Agents Phase 4
25 Adrenergic Antagonists Phase 4
26 Adrenergic beta-Antagonists Phase 4
27 Anti-Arrhythmia Agents Phase 4
28 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
29 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
30 Endothelial Growth Factors Phase 4,Phase 2,Phase 3
31 Mitomycins Phase 4,Phase 2,Phase 3
32 Antimetabolites Phase 4,Phase 2,Phase 3
33 Antimetabolites, Antineoplastic Phase 4
34 Immunosuppressive Agents Phase 4
35
Povidone-iodine Approved Phase 3 25655-41-8
36
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
37
Tranilast Approved, Investigational Phase 3 53902-12-8 93543
38
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
39
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
40 Anti-Bacterial Agents Phase 2, Phase 3
41 Antibiotics, Antitubercular Phase 2, Phase 3
42 cadexomer iodine Phase 3
43
Iodine Phase 3 7553-56-2 807
44 Povidone Phase 3
45 Analgesics Phase 3
46 Analgesics, Non-Narcotic Phase 3
47 Anti-Allergic Agents Phase 3
48 Anti-Inflammatory Agents, Non-Steroidal Phase 3
49 Antirheumatic Agents Phase 3
50 calcium channel blockers Phase 3

Interventional clinical trials:

(show all 40)
id Name Status NCT ID Phase
1 Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension Unknown status NCT02047630 Phase 4
2 Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes Completed NCT02136589 Phase 4
3 Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT01253902 Phase 4
4 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02061683 Phase 4
5 Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Completed NCT01298700 Phase 4
6 Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients. Completed NCT01997489 Phase 4
7 20- Versus 23- Gauge System for Pars Plana Vitrectomy Completed NCT00411970 Phase 4
8 Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00804648 Phase 4
9 Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma Completed NCT01922154 Phase 4
10 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose Recruiting NCT02017327 Phase 4
11 Strategies for Management of Recurrent Pterygium Not yet recruiting NCT02530801 Phase 4
12 A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension Completed NCT01830140 Phase 3
13 Evaluation of Tranilast to Treat Pterygium Before Excision Completed NCT01003613 Phase 3
14 Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma Completed NCT02901236 Phase 2, Phase 3
15 Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study Completed NCT02342392 Phase 2, Phase 3
16 Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy Active, not recruiting NCT01976923 Phase 3
17 A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension Completed NCT00538304 Phase 2
18 Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma Completed NCT01739244 Phase 2
19 A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension Completed NCT01379144 Phase 2
20 A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma Completed NCT01936389 Phase 2
21 A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease Completed NCT01135511 Phase 2
22 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
23 Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU) Completed NCT01081574 Phase 1, Phase 2
24 Limbal Epithelial Stem Cell Transplantation: a Phase II Multicenter Trial Recruiting NCT02318485 Phase 2
25 Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection Recruiting NCT02486484 Phase 2
26 Bevacizumab Injection for Recurrent Pterygium Completed NCT02007174 Phase 1
27 Effect of Ranibizumab on Malignant Conjunctival Neoplasia Completed NCT00456495 Phase 1
28 Conjunctival Flora Patterns After Serial Intravitreal Injections in Diabetic Patients Unknown status NCT02337972
29 A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye Unknown status NCT01531842
30 Etiology and Prevalence of Peripheral Arterial Disease Completed NCT00005142
31 Resistance to Antibiotics in Patients Receiving Eye Injections Completed NCT02126423
32 Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab Completed NCT00892398
33 Alterations of Conjunctival Microcirculation in Brain Dead Patients Completed NCT02483273
34 Animal Allergy in Korean Pet Owners, Pet-related Industry Workers, and Laboratory Animal Reseachers Completed NCT03101618
35 Clinical Applications of Advanced Ophthalmic Imaging Recruiting NCT03135327
36 Aqueous Dynamics and Glaucoma Surgeries Recruiting NCT02839590
37 Screening for Research Participants Recruiting NCT00655096
38 Uveitis/Intraocular Inflammatory Disease Biobank (iBank) Recruiting NCT02656381
39 Single Blind Randomized Study to Determine the Sensitivity and Specificity of 2 Non-invasive Markers of Early Coronary Disease Terminated NCT01742156
40 Tissue Studies of Human Eye Diseases Terminated NCT00001310

Search NIH Clinical Center for Conjunctival Vascular Disease

Genetic Tests for Conjunctival Vascular Disease

Anatomical Context for Conjunctival Vascular Disease

MalaCards organs/tissues related to Conjunctival Vascular Disease:

39
Eye

Publications for Conjunctival Vascular Disease

Variations for Conjunctival Vascular Disease

Expression for Conjunctival Vascular Disease

Search GEO for disease gene expression data for Conjunctival Vascular Disease.

Pathways for Conjunctival Vascular Disease

GO Terms for Conjunctival Vascular Disease

Sources for Conjunctival Vascular Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....